A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.
Christophe le TourneauJean-Pierre DelordNuria KoteckiEdith BorcomanCarlos Gomez-RocaSégolène HescotChristiane JungelsAnne Vincent-SalomonVincent CockenpotLauriane EberstAudrey MoléWael JdeyFrançoise BonoVéronique Trochon-JosephHélène ToussaintChristelle ZandanelOlga AdamiecOlivier de BeaumontPhilippe Alexandre CassierPublished in: British journal of cancer (2020)
Clinical trial registration (NCT number): NCT03579628.